Literature DB >> 15652663

Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines.

Maureen Dennehy1, Anna-Lise Williamson.   

Abstract

A wide range of recombinant BCG vaccine candidates containing foreign viral, bacterial, parasite or immunomodulatory genetic material have been developed and evaluated, primarily in animal models, for immune response to the foreign antigen. This review considers some of the factors that may influence the immunogenicity of these vaccines. The influence of levels and timing of expression of the foreign antigen and the use of targeting sequences are considered in the first section. Genetic and functional stability of rBCG is reviewed in the second section. In the last section, the influence of dose and route of immunization, strain of BCG and the animal model used are discussed.

Mesh:

Substances:

Year:  2005        PMID: 15652663     DOI: 10.1016/j.vaccine.2004.08.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.

Authors:  Michela Sali; Gabriele Di Sante; Alessandro Cascioferro; Antonella Zumbo; Chiara Nicolò; Valentina Donà; Stefano Rocca; Annabella Procoli; Matteo Morandi; Francesco Ria; Giorgio Palù; Giovanni Fadda; Riccardo Manganelli; Giovanni Delogu
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  OmpL1 is an extracellular matrix- and plasminogen-interacting protein of Leptospira spp.

Authors:  Luis G V Fernandes; Monica L Vieira; Karin Kirchgatter; Ivy J Alves; Zenaide M de Morais; Silvio A Vasconcellos; Eliete C Romero; Ana L T O Nascimento
Journal:  Infect Immun       Date:  2012-07-16       Impact factor: 3.441

Review 3.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

4.  Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.

Authors:  Bryan E Hart; Rose Asrican; So-Yon Lim; Jaimie D Sixsmith; Regy Lukose; Sommer J R Souther; Swati D G Rayasam; Joseph W Saelens; Ching-Ju Chen; Sarah A Seay; Linda Berney-Meyer; Leslie Magtanong; Kim Vermeul; Priyadharshini Pajanirassa; Amanda E Jimenez; Tony W Ng; David M Tobin; Steven A Porcelli; Michelle H Larsen; Joern E Schmitz; Barton F Haynes; William R Jacobs; Sunhee Lee; Richard Frothingham
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

5.  Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.

Authors:  Mark J Cayabyab; Birgit Korioth-Schmitz; Yue Sun; Angela Carville; Harikrishnan Balachandran; Ayako Miura; Kevin R Carlson; Adam P Buzby; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

6.  Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.

Authors:  I Bontempi; K Leal; E Prochetto; G Díaz; G Cabrera; A Bortolotti; H R Morbidoni; S Borsuk; O Dellagostin; I Marcipar
Journal:  Clin Exp Immunol       Date:  2020-07-06       Impact factor: 4.330

7.  Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.

Authors:  Joan Joseph; Raquel Fernández-Lloris; Elías Pezzat; Narcís Saubi; Pere-Joan Cardona; Beatriz Mothe; Josep Maria Gatell
Journal:  J Biomed Biotechnol       Date:  2010-06-27

8.  Optimisation of bioluminescent reporters for use with mycobacteria.

Authors:  Nuria Andreu; Andrea Zelmer; Taryn Fletcher; Paul T Elkington; Theresa H Ward; Jorge Ripoll; Tanya Parish; Gregory J Bancroft; Ulrich Schaible; Brian D Robertson; Siouxsie Wiles
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

9.  Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Authors:  Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques.

Authors:  Jaimie D Sixsmith; Michael W Panas; Sunhee Lee; Geoffrey O Gillard; KeriAnn White; Michelle A Lifton; Harikrishnan Balachandran; Linh Mach; John P Miller; Christy Lavine; C Todd DeMarco; Georgia D Tomaras; Connie Gee; Steven A Porcelli; Michelle H Larsen; Richard Frothingham; Joern E Schmitz; William R Jacobs; Barton F Haynes; Norman L Letvin; Birgit Korioth-Schmitz
Journal:  Clin Vaccine Immunol       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.